Dimerix appoints Medical Advisory Board

Dimerix has appointed a Medical Advisory Board (MAB) to help guide the company’s DMX-200 clinical programme.

The MAB will provide clinical and strategic input into the company’s lead programme, DMX-200 in chronic kidney disease and will provide guidance to the company as it shapes and progresses its DMX-200 programmes. The MAB will have no formal governance role.

Associate Professor David Packham (MD, MB, BS (Hons), FRCP, FRACP) will lead the MAB in the position of Chair, where he will be joined by:

  • Professor David Power, MD, MB, BS, PhD, MRCP(UK), FRACP
  • Daniel Cattran, MD, FRCP (C)
  • Alessia Fornoni, MD, PhD, FASN
  • Jonathan Hogan, MD

Kathy Harrison, group CEO at Dimeric, said: “We are delighted to have attracted such a respected group of nephrologists to join this inaugural MAB, particularly as the DMX-200 programme in chronic kidney disease moves closer to phase 2b trials.”

“The formation of this board will help drive forward the clear clinical potential of our DMX-200 programme. The MAB members' insights and guidance will prove invaluable as we design and advance our programme.”

The MAB is compensated for its time through a combination cash and equity based remuneration, with the total number of shares to be issued of 2,743,000 (pre consolidation) and a package of options to be issued to the approximate value of $10,000 the precise number and exercise price to be determined.

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Regulatory

Post-Brexit border paperwork and inspections postponed for life sciences sector

The six month extension will allow life science companies to the make necessary alterations to their supply chains to accommodate for the novel post-Brexit border paperwork
Subscribe now